Pliant Therapeutics Inc Ordinary Shares PLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PLRX is a good fit for your portfolio.
News
-
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
-
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
-
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
-
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
-
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
Amazon and JPMorgan stocks fall, Rivian and DraftKings shares rally, and other stocks on the move
Trading Information
- Previous Close Price
- $10.58
- Day Range
- $10.29–10.60
- 52-Week Range
- $10.29–20.23
- Bid/Ask
- $10.50 / $10.52
- Market Cap
- $634.63 Mil
- Volume/Avg
- 295,875 / 503,065
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,548.78
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 158
- Website
- https://www.pliantrx.com
Comparables
Valuation
|
Metric
|
PLRX
|
EWTX
|
DYN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.46 | 3.19 | 6.21 |
Price/Sales | 2,548.78 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
PLRX
EWTX
DYN
Financial Strength
|
Metric
|
PLRX
|
EWTX
|
DYN
|
|---|---|---|---|
Quick Ratio | 15.95 | 36.49 | 20.28 |
Current Ratio | 16.12 | 37.08 | 21.83 |
Interest Coverage | −138.69 | — | — |
Quick Ratio
PLRX
EWTX
DYN
Profitability
|
Metric
|
PLRX
|
EWTX
|
DYN
|
|---|---|---|---|
Return on Assets (Normalized) | −23.39% | −23.18% | −77.53% |
Return on Equity (Normalized) | −25.61% | −24.45% | −94.92% |
Return on Invested Capital (Normalized) | −29.08% | −28.92% | −88.19% |
Return on Assets
PLRX
EWTX
DYN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Cxmwdlnn | Ksjph | $624.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fldtqprh | Ntdyhy | $121.4 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ttqxczzc | Wfxhsjb | $112.8 Bil | |||
| Moderna Inc
MRNA
| Gbvmykltl | Sgvc | $44.4 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ndsvyyvs | Jynsr | $31.5 Bil | |||
| argenx SE ADR
ARGX
| Wldxvzqgq | Byr | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Bcbyvdf | Ppj | $19.2 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xgfptwfd | Qrqkbd | $15.4 Bil | |||
| United Therapeutics Corp
UTHR
| Dmhdrzls | Zrn | $13.8 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tngptkgwfl | Rvgbns | $11.7 Bil |